LHLeo Heyndrickx

Leo Heyndrickx

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leo Heyndrickx has a total of 204 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In search for tick-borne encephalitis virus and Rickettsia in Belgian Ixodes ricinus ticks: Evidence of rickettsia felis

    by Jasmine Coppens, Anke Stoefs, Jolien Baeyens, Hanne Rasson, Leo Heyndrickx, Jacob Verschueren, Bart K.M. Jacobs, Isra Deblauwe, Kevin K. Ariën, Marjan Van Esbroeck


  • Open Access

    Celluloepidemiology—A paradigm for quantifying infectious disease dynamics on a population level

    by My K. Ha, Anna Postovskaya, Maria Kuznetsova, Pieter Meysman, Vincent Van Deuren, Sabrina Van Ierssel, Hans De Reu, Jolien Schippers, Karin Peeters, Hajar Besbassi, et al.

    To complement serology as a tool in public health interventions, we introduced the “celluloepidemiology” paradigm where we leveraged pathogen-specific T cell responses at a population level to advance our epidemiological understanding of infectious diseases, using SARS-CoV-2 as a model. Applying flow cytometry and machine learning on data from more than 500 individuals, we showed that the number of T cells with positive expression of functional markers not only could distinguish patients who recovered from COVID-19 from controls and pre-COVID donors but also identify previously unrecognized asymptomatic patients from mild, moderate, and severe recovered patients. The celluloepidemiology approach was uniquely capable to differentiate health care worker groups with different SARS-CoV-2 exposures from each other. T cell receptor (TCR) profiling strengthened our analysis by revealing that SARS-CoV-2–specific TCRs were more abundant in patients than in controls. We believe that adding data on T cell reactivity will complement serology and augment the value of infection morbidity modeling for populations.


  • Open Access

    Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

    by Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Daphnée Georges, Sarah Houben, Véronique Olislagers, Alexandra Waegemans, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, et al.


  • Open Access

    Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients

    by Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, Véronique Olislagers, Daphnée Georges, Alexandra Waegemans, Pieter Pannus, Anne Lemy, Maria E. Goossens, Isabelle Desombere, et al.


  • Open Access

    Chikungunya Virus’ High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells

    by Lien De Caluwé, Leo Heyndrickx, Sandra Coppens, Katleen Vereecken, Miguel E. Quiñones-Mateu, Andres Merits, Kevin K. Ariën, Koen Bartholomeeusen

    Chikungunya virus (CHIKV) is an emerging arthropod-borne virus that has spread globally during the last two decades. The virus is mainly transmitted by Aedes aegypti and Aedes albopictus mosquitos and is thus capable of replicating in both human and mosquito cells. CHIKV has a broad tropism in vivo, capable of replicating in various tissues and cell types but largely excluding blood cells. This was reflected in vitro by a broad array of adherent cell lines supporting CHIKV infection. One marked exception to this general rule is the resistance of the lung cancer-derived A549 cell line to CHIKV infection. We verified that A549 cells were restrictive to infection by multiple alphaviruses while being completely permissive to flavivirus infection. The adaptive growth of a primary CHIKV strain through multiple passages allowed the emergence of a CHIKV strain that productively infected A549 cells while causing overt cytopathic effects and without a fitness cost for replication in otherwise CHIKV-susceptible cells. Whole genome sequencing of polyclonal and monoclonal preparations of the adapted virus showed that a limited number of mutations consistently emerged in both structural (2 mutations in E2) and non-structural proteins (1 mutation in nsP1 and 1 mutation in nsP2). The introduction of the adaptive mutations, individually or in combinations, into a wild-type molecular clone of CHIKV allowed us to determine the relative contributions of the mutations to the new phenotype. We found that the mutations in the E2 envelope protein and non-structural proteins contributed significantly to the acquired phenotype. The nsP mutations were introduced in a split-genome trans-replicase assay to monitor their effect on viral genome replication efficiency. Interestingly, neither mutation supported increased viral genomic replication in either Vero or A549 cells.


  • Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

    by Joachim Mariën, Johan Michiels, Leo Heyndrickx, Antoine Nkuba-Ndaye, Ann Ceulemans, Koen Bartholomeeusen, Joule Madinga, Placide Mbala-Kingebeni, Veerle Vanlerberghe, Steve Ahuka-Mundeke, et al.


  • Open Access

    A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity

    by Annemieke Smet, Tom Breugelmans, Johan Michiels, Kevin Lamote, Wout Arras, Joris G. De Man, Leo Heyndrickx, Anne Hauner, Manon Huizing, Surbhi Malhotra-Kumar, et al.

    BACKGROUND: SARS-CoV-2 infection induces mucin overexpression, further promoting disease. Given that mucins are critical components of innate immunity, unraveling their expression profiles that dictate the course of disease could greatly enhance our understanding and management of COVID-19. METHODS: Using validated RT-PCR assays, we assessed mucin mRNA expression in the blood of patients with symptomatic COVID-19 compared with symptomatic patients without COVID-19 and healthy controls and correlated the data with clinical outcome parameters. Additionally, we analyzed mucin expression in mucus and lung tissue from patients with COVID-19 and investigated the effect of drugs for COVID-19 treatment on SARS-CoV-2–induced mucin expression in pulmonary epithelial cells. RESULTS: We identified a dynamic blood mucin mRNA signature that clearly distinguished patients with symptomatic COVID-19 from patients without COVID-19 based on expression of MUC1 , MUC2 , MUC4 , MUC6 , MUC13 , MUC16 , and MUC20 (AUC ROC of 91.8%; sensitivity and specificity of 90.6% and 93.3%, respectively) and that discriminated between mild and critical COVID-19 based on the expression of MUC16, MUC20, and MUC21 (AUC ROC of 89.1%; sensitivity and specificity of 90.0% and 85.7%, respectively). Differences in the transcriptional landscape of mucins in critical cases compared with mild cases identified associations with COVID-19 symptoms, respiratory support, organ failure, secondary infections, and mortality. Furthermore, we identified different mucins in the mucus and lung tissue of critically ill COVID-19 patients and showed the ability of baricitinib, tocilizumab, favipiravir, and remdesivir to suppress expression of SARS-CoV-2–induced mucins. CONCLUSION: This multifaceted blood mucin mRNA signature showed the potential role of mucin profiling in diagnosing, estimating severity, and guiding treatment options in patients with COVID-19. FUNDING: The Antwerp University Research and the Research Foundation Flanders COVID-19 funds.


  • Open Access

    Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

    by Joachim Mariën, Ann Ceulemans, Johan Michiels, Leo Heyndrickx, Karen Kerkhof, Nikki Foque, Marc-Alain Widdowson, Laure Mortgat, Els Duysburgh, Isabelle Desombere, et al.


  • Open Access

    SARS-CoV-2 Prevalence and Seroprevalence among Healthcare Workers in Belgian Hospitals: Baseline Results of a Prospective Cohort Study

    by Laure Mortgat, Cyril Barbezange, Natalie Fischer, Leo Heyndrickx, Veronik Hutse, Isabelle Thomas, Bea Vuylsteke, Kevin Arien, Isabelle Desombere, Els Duysburgh

    Background: Given the current SARS-CoV-2 pandemic and the occurrence of a second wave, assessing the burden of disease among health care workers (HCWs) is crucial. We aim to document the prevalence of SARS-CoV-2 and the seroprevalence of anti-SARS-CoV-2 IgG among HCWs in Belgian hospitals, and to study potential risk factors for the infection in order to guide infection prevention and control (IPC) measures in healthcare institutions. Methods: We performed a cross-sectional analysis of the baseline results (April 22 - April 26) of an ongoing cohort study. All staff who were present in the hospital during the sampling period and whose profession involved contact with patients were eligible. Fourteen hospitals across Belgium and 50 HCW per hospital were randomly selected. RT-qPCR was performed to detect SARS-CoV-2 RNA on nasopharyngeal swabs, and a semi-quantitative IgG ELISA was used to detect anti-SARS-CoV-2 antibodies in sera. Individual characteristics likely to be associated with seropositivity were collected using an online questionnaire. Findings: 698 participants completed the questionnaire; 80.8% were women, median age was 39.5, and 58.5% were nurses. Samples were collected on all 699 participants. The weighted anti-SARS-CoV-2 IgG seroprevalence was 7.7% (95%CI, 4.7%-12.2%), while 1.1% (95%CI, 0.4%-3.0%) of PCR results were positive. Unprotected contact with a confirmed case was the only factor associated with seropositivity (PR 2.16, 95% CI, 1.4-3.2). Interpretation: Most Belgian HCW did not show evidence of SARS-CoV-2 infection by late April 2020, and unprotected contact was the most important risk factor. This confirms the importance of widespread availability of protective equipment and use of adequate IPC measures in hospital settings.


  • Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1–Infected Individuals from Guinea-Bissau and Denmark

    by Marie Borggren, Sanne Skov Jensen, Leo Heyndrickx, Angelica A. Palm, Jan Gerstoft, Gitte Kronborg, Bo Langhoff Hønge, Sanne Jespersen, Zacarias José da Silva, Ingrid Karlsson, et al.

    The development of therapeutic and prophylactic HIV vaccines for African countries is urgently needed, but the question of what immunogens to use needs to be answered. One approach is to include HIV envelope immunogens derived from HIV-positive individuals from a geographically concentrated epidemic with more limited viral genetic diversity for a region-based vaccine. To address if there is a basis for a regional selected antibody vaccine, we have screened two regionally separate cohorts from Guinea-Bissau and Denmark for neutralizing antibody activity and antibody-dependent cellular cytotoxicity (ADCC) against local and non-local circulating HIV-1 strains. The neutralizing activity did not demonstrate higher potential against local circulating strains according to geography and subtype determination, but the plasma from Danish individuals demonstrated significantly higher inhibitory activity than the plasma from individuals from Guinea-Bissau against both local and non-local virus strains. Interestingly, an opposite pattern was observed with ADCC activity, where Guinea-Bissau individual plasma demonstrated higher activity than Danish plasma and was specifically against the local circulating subtype. Thus, on basis of samples from these two cohorts no local-specific neutralizing activity was detected, but a local ADCC response was identified in the Guinea-Bissau samples, suggesting potential use of regional immunogens for an ADCC inducing vaccine.